{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:15:43Z","timestamp":1785575743581,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"am","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.purol.2019.11.003","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T22:30:57Z","timestamp":1575585057000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: Retrospective study in a French peripheral hospital"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Jeglinschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schirmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.purol.2019.11.003_bib0140","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1166-7087(16)30704-7","article-title":"CCAFU French national guidelines 2016\u20132018 on bladder cancer","volume":"27","author":"Roupr\u00eat","year":"2016","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2019.11.003_bib0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines. Non-muscle-invasive Bladder Cancer (TaT1 and CIS)","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.purol.2019.11.003_bib0150","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2016.165","article-title":"Bladder cancer: low adherence to guidelines in non-muscle invasive disease","volume":"13","author":"Van Rhijn","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.11.003_bib0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/S1677-5538.IBJU.2015.0122","article-title":"Are we following the guidelines on non-muscle invasive bladder cancer?","volume":"42","author":"Reis","year":"2016","journal-title":"Int Braz J Urol"},{"issue":"6","key":"10.1016\/j.purol.2019.11.003_bib0160","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"issue":"1\u20132","key":"10.1016\/j.purol.2019.11.003_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5489\/cuaj.3143","article-title":"Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta","volume":"10","author":"Gotto","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"10.1016\/j.purol.2019.11.003_bib0170","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2009.06.009","article-title":"Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association","volume":"19","author":"Descazeaud","year":"2009","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2019.11.003_bib0175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2005.11.010","article-title":"Current practice int the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2019.11.003_bib0180","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S1569-9056(16)60218-X","article-title":"Discrepancy between guidelines and daily practice in the management of non-muscle invasive bladder cancer (NMIBC): results of a European survey","volume":"15","author":"Aziz","year":"2016","journal-title":"Eur Urol Suppl"},{"issue":"2","key":"10.1016\/j.purol.2019.11.003_bib0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1569-9056(11)60424-7","article-title":"Initial BCG instillation is under-used in T1 bladder cancer","volume":"10","author":"Jahnson","year":"2011","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"10.1016\/j.purol.2019.11.003_bib0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000321926","article-title":"Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblastic Therapy Italian Study","volume":"86","author":"Gontero","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.purol.2019.11.003_bib0195","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.ijsu.2014.08.292","article-title":"Intravesical BCG in Hight risk non muscle invasive bladder cancer: Patient outcomes and adherence to EAU Guidelines","volume":"12","author":"Gates","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.purol.2019.11.003_bib0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bju.13265","article-title":"Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series","volume":"117","author":"Gendy","year":"2016","journal-title":"BJU Int"},{"issue":"Suppl 2","key":"10.1016\/j.purol.2019.11.003_bib0205","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S1166-7087(13)70049-6","article-title":"Recommandations en onco-urologie 2013 du CCAFU\u00a0: tumeurs de la vessie","volume":"23","author":"Pfister","year":"2013","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.purol.2019.11.003_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ygyno.2012.07.001","article-title":"Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients","volume":"127","author":"Jorgensen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.purol.2019.11.003_bib0215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1464-410X.2012.11060.x","article-title":"Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey","volume":"110","author":"Nielsen","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.purol.2019.11.003_bib0220","first-page":"135","article-title":"Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction","volume":"6","author":"Taylor","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.11.003_bib0225","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.clgc.2016.06.014","article-title":"Association between number of endoscopic resections and utilization of Bacillus Calmette-Gu\u00e9rin therapy for patients with high-grade, nonmuscle-invasive bladder cancer","volume":"15","author":"Lenis","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"23","key":"10.1016\/j.purol.2019.11.003_bib0230","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.purol.2019.11.003_bib0235","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4111\/icu.2016.57.S1.S26","article-title":"Treatment of bladder cancer in the elderly","volume":"57","author":"Erlich","year":"2016","journal-title":"Investig Clin Urol"},{"issue":"4","key":"10.1016\/j.purol.2019.11.003_bib0240","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2019.11.003_bib0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000430501","article-title":"Does the compliance to intravesical bcg differ between common clinical practice and international multicentric trials?","volume":"96","author":"Serretta","year":"2016","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.purol.2019.11.003_bib0250","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13187-014-0649-3","article-title":"Educational opportunities in bladder cancer: increasng cystoscopic adherence and the availability of smoking-cessation programs","volume":"29","author":"Kowalkowski","year":"2014","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.purol.2019.11.003_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/421709","article-title":"Surveillance and treatment of non-muscle-invasive bladder cancer in the USA","volume":"2012","author":"Barocas","year":"2012","journal-title":"Adv Urol"},{"issue":"5","key":"10.1016\/j.purol.2019.11.003_bib0260","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/21681805.2013.769461","article-title":"High-grade non-muscle-invasive bladder cancer: Is re-resection necessary in all patients before intravesical bacillus Calmette\u2013Gu\u00e9rin treatment?","volume":"47","author":"Holm\u00e4ng","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.purol.2019.11.003_bib0265","first-page":"269","article-title":"The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer","volume":"6","author":"Vasdev","year":"2012","journal-title":"Ecancermedicalscience"},{"issue":"Suppl 1","key":"10.1016\/j.purol.2019.11.003_bib0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12764","article-title":"Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion","volume":"114","author":"Rao","year":"2014","journal-title":"BJU Int"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708719306116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:32:08Z","timestamp":1761114728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708719306116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1166708719306116"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.003","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: Retrospective study in a French peripheral hospital","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2019.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}